Sugi Predict

Sugi Predict / Compounds / SCHEMBL10116634

SCHEMBL10116634

SCHEMBL10116634

CC(C)S(=O)(=O)Nc1ccc(C(=O)Nc2ccc(F)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.61
▸ KMT2A Q03164 4/20 0.61
▸ PTPN1 P18031 1/20 0.59
▸ MITF O75030 1/20 0.58
▸ RAB9A P51151 4/20 0.57
▸ NPC1 O15118 3/20 0.57
▸ ATM Q13315 1/20 0.57
▸ CXCR2 P25025 2/20 0.57
▸ KDM4E B2RXH2 1/20 0.56
▸ LMNA P02545 1/20 0.56
▸ POLB P06746 2/20 0.54
▸ TDP1 Q9NUW8 1/20 0.54
▸ HTT P42858 1/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ SNCA P37840 1/20 0.52
▸ GRIA2 P42262 1/20 0.52
▸ NOS1 P29475 1/20 0.51
▸ NOS2 P35228 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10116617 0.89 GRIA2 (0.56) MEN1KMT2APTPN1MITFRAB9A
SCHEMBL10116458 0.87 GRIA4 (0.60) MEN1KMT2APTPN1RAB9ANPC1
SCHEMBL10116526 0.87 KDM4E (0.74) MEN1KMT2ARAB9ANPC1KDM4E
SCHEMBL10116460 0.87 NPC1 (0.67) MEN1KMT2ARAB9ANPC1KDM4E
SCHEMBL10116572 0.86 TRPV1 (0.62) RAB9ANPC1KDM4ELMNASMN1; SMN2
SCHEMBL10116464 0.85 LMNA (0.76) RAB9ANPC1KDM4ELMNASMN1; SMN2
SCHEMBL10116468 0.85 KMT2A (0.60) MEN1KMT2ARAB9ANPC1KDM4E
SCHEMBL10802804 0.85 KDM4E (0.56) MEN1KMT2ARAB9AKDM4ELMNA
SCHEMBL10116627 0.85 LMNA (0.56) MEN1KMT2ARAB9ANPC1KDM4E
SCHEMBL10116477 0.85 NPC1 (0.59) MEN1KMT2ARAB9ANPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 — — US disclosed
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 — — US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 — — US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 — — US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 — — US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 — — US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 — — US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 — — US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 — — US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 — — US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R MEN1 2876/4885KMT2A 2912/4885PTPN1 312/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R MEN1 2932/4885KMT2A 2768/4885PTPN1 353/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R MEN1 2926/4885KMT2A 2953/4885PTPN1 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.